Skip to main content
. Author manuscript; available in PMC: 2015 Dec 15.
Published in final edited form as: Biochem Pharmacol. 2014 Oct 12;92(4):590–598. doi: 10.1016/j.bcp.2014.09.021

Figure 2.

Figure 2

Hyperoside Induces Nur77 dependent transcriptional activation in RVSMCs. (A) RVSMCs were treated with hyperoside (HYP) (5 μmol/L) for indicated time points. The expression of Nur77 was then determined by Western blot analysis (n=4, *P<0.05 vs time at 0). (B) RVSMCs were treated with increasing concentrations of hyperoside (HYP) for 12 hrs and the expression of Nur77 was determined by Western blot analysis (n=4. *P<0.05 vs treatment with vehicle). (C) RVSMCs were treated with either vehicle or hyperoside (HYP) (5μmol/L) for 12 hrs. The localization of Nur77 was determined by immunofluorescent staining. (D) RVSMCs were transfected with NBRE-Luc reporter plasmid. 48 hrs after transfection, RVSMCs were stimulated with different doses of hyperoside (HYP) for 12 hr and the luciferase activity was then determined (n=5, *P<0.05 vs treatment with vehicle).